Company intelligence / Profile preview
Elicera Therapeutics AB
Gothenburg, Swedenelicera.com ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Phase 1
01
Overview
Elicera Therapeutics has two main technology areas—CAR T-cell therapies and oncolytic viruses—both enhanced by its iTANK platform. Its lead oncolytic virus candidate, ELC‑100, received Orphan Drug Designation from the FDA for pancreatic neuroendocrine tumors; final data from the first part of its ongoing Phase I/II trial are expected mid‑2025. The lead CAR T program, ELC‑301 for B-cell lymphoma, showed a complete response in the first patient at lowest dose level with very mild side effects in early clinical results. The company also has preclinical programs targeting solid cancers and brain tumors[6][7].
- Therapeutic areas
- Oncology
- Modalities
- CAR T-cell therapies (cell therapy)Oncolytic viruses (gene therapy)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Vecura R&D division at Karolinska University HospitalUppsala University for automated production of ELC–401Swedish Cancer Society support for clinical study planning[3]
Beyond the preview
Go deeper on Elicera Therapeutics AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Elicera Therapeutics AB.